Financials data is unavailable for this security.
View more
Year on year Arrowhead Pharmaceuticals Inc had net income fall 25.00% from a loss of 140.85m to a larger loss of 176.06m despite a 75.89% increase in revenues from 138.29m to 243.23m.
Gross margin | -- |
---|---|
Net profit margin | -72.56% |
Operating margin | -73.39% |
Return on assets | -25.18% |
---|---|
Return on equity | -43.62% |
Return on investment | -32.18% |
More ▼
Cash flow in USDView more
In 2022, cash reserves at Arrowhead Pharmaceuticals Inc fell by 76.43m. Cash Flow from Financing totalled 65.19m or 26.80% of revenues. In addition the company used 136.13m for operations while cash used for investing totalled 5.42m.
Cash flow per share | -1.57 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 3.76 |
---|---|
Tangible book value per share | 3.65 |
More ▼
Balance sheet in USDView more
Current ratio | 2.92 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼